Ghent University Academic Bibliography

Advanced

AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model

Adriaan Verhelle, Nair Nisha, Inge Everaert UGent, Wouter Van Overbeke, Lynn Supply UGent, Olivier Zwaenepoel UGent, Cindy Peleman, Jo Van Dorpe UGent, Tony Lahoutte, Nick Devoogdt, et al. (2017) HUMAN MOLECULAR GENETICS. 26(7). p.1353-1364
abstract
Gelsolin amyloidosis is a dominantly inherited, incurable type of amyloidosis. A single point mutation in the gelsolin gene (G654A is most common) results in the loss of a Ca2+ binding site in the second gelsolin domain. Consequently, this domain partly unfolds and exposes an otherwise buried furin cleavage site at the surface. During secretion of mutant plasma gelsolin consecutive cleavage by furin and MT1-MMP results in the production of 8 and 5 kDa amyloidogenic peptides. Nanobodies that are able to (partly) inhibit furin or MT1-MMP proteolysis have previously been reported. In this study, the nanobodies have been combined into a single bispecific format able to simultaneously shield mutant plasma gelsolin from intracellular furin and extracellular MT1-MMP activity. We report the successful in vivo expression of this bispecific nanobody following adeno-associated virus serotype 9 gene therapy in gelsolin amyloidosis mice. Using SPECT/CT and immunohistochemistry, a reduction in gelsolin amyloid burden was detected which translated into improved muscle contractile properties. We conclude that a nanobody-based gene therapy using adeno-associated viruses shows great potential as a novel strategy in gelsolin amyloidosis and potentially other amyloid diseases.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
ADENOASSOCIATED VIRAL VECTORS, GENE-THERAPY, FAMILIAL AMYLOIDOSIS, DIRECTED EVOLUTION, IN-VITRO, ACTIN, EXPRESSION, VIRUSES, BINDING, PROTEIN
journal title
HUMAN MOLECULAR GENETICS
Hum. Mol. Genet.
volume
26
issue
7
pages
1353 - 1364
Web of Science type
Article
Web of Science id
000400911300012
ISSN
0964-6906
1460-2083
DOI
10.1093/hmg/ddx056
language
English
UGent publication?
yes
classification
A1
additional info
correction [author name] published in: Hum. Mol. Genet. (2017) 26(15), 3030 ; DOI 10.1093/hmg/ddx207
copyright statement
I have transferred the copyright for this publication to the publisher
id
8511282
handle
http://hdl.handle.net/1854/LU-8511282
date created
2017-02-25 14:26:41
date last changed
2017-09-20 12:58:46
@article{8511282,
  abstract     = {Gelsolin amyloidosis is a dominantly inherited, incurable type of amyloidosis. A single point mutation in the gelsolin gene (G654A is most common) results in the loss of a Ca2+ binding site in the second gelsolin domain. Consequently, this domain partly unfolds and exposes an otherwise buried furin cleavage site at the surface. During secretion of mutant plasma gelsolin consecutive cleavage by furin and MT1-MMP results in the production of 8 and 5 kDa amyloidogenic peptides. Nanobodies that are able to (partly) inhibit furin or MT1-MMP proteolysis have previously been reported. In this study, the nanobodies have been combined into a single bispecific format able to simultaneously shield mutant plasma gelsolin from intracellular furin and extracellular MT1-MMP activity. We report the successful in vivo expression of this bispecific nanobody following adeno-associated virus serotype 9 gene therapy in gelsolin amyloidosis mice. Using SPECT/CT and immunohistochemistry, a reduction in gelsolin amyloid burden was detected which translated into improved muscle contractile properties. We conclude that a nanobody-based gene therapy using adeno-associated viruses shows great potential as a novel strategy in gelsolin amyloidosis and potentially other amyloid diseases.},
  author       = {Verhelle, Adriaan and Nisha, Nair and Everaert, Inge and Van Overbeke, Wouter and Supply, Lynn and Zwaenepoel, Olivier and Peleman, Cindy and Van Dorpe, Jo and Lahoutte, Tony and Devoogdt, Nick and Derave, Wim and Marinee, Chuah K and VandenDriessche, Thierry and Gettemans, Jan},
  issn         = {0964-6906},
  journal      = {HUMAN MOLECULAR GENETICS},
  keyword      = {ADENOASSOCIATED VIRAL VECTORS,GENE-THERAPY,FAMILIAL AMYLOIDOSIS,DIRECTED EVOLUTION,IN-VITRO,ACTIN,EXPRESSION,VIRUSES,BINDING,PROTEIN},
  language     = {eng},
  number       = {7},
  pages        = {1353--1364},
  title        = {AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model},
  url          = {http://dx.doi.org/10.1093/hmg/ddx056},
  volume       = {26},
  year         = {2017},
}

Chicago
Verhelle, Adriaan, Nair Nisha, Inge Everaert, Wouter Van Overbeke, Lynn Supply, Olivier Zwaenepoel, Cindy Peleman, et al. 2017. “AAV9 Delivered Bispecific Nanobody Attenuates Amyloid Burden in the Gelsolin Amyloidosis Mouse Model.” Human Molecular Genetics 26 (7): 1353–1364.
APA
Verhelle, A., Nisha, N., Everaert, I., Van Overbeke, W., Supply, L., Zwaenepoel, O., Peleman, C., et al. (2017). AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model. HUMAN MOLECULAR GENETICS, 26(7), 1353–1364.
Vancouver
1.
Verhelle A, Nisha N, Everaert I, Van Overbeke W, Supply L, Zwaenepoel O, et al. AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model. HUMAN MOLECULAR GENETICS. 2017;26(7):1353–64.
MLA
Verhelle, Adriaan, Nair Nisha, Inge Everaert, et al. “AAV9 Delivered Bispecific Nanobody Attenuates Amyloid Burden in the Gelsolin Amyloidosis Mouse Model.” HUMAN MOLECULAR GENETICS 26.7 (2017): 1353–1364. Print.